Home › Acute Kidney Injury › NCT07734636
A Prompt REstart Study of Renin-Angiotensin System Inhibitors After Acute Kidney Injury
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: * Age ≥ 18 years * Pre-admission RASi use for Class I indication (e.g., heart failure, kidney disease) * RASi stopped in the setting of AKI (defined by ≥1.5x baseline SCr) * AKI in recovery (defined by a decrease in SCr by ≥0.3mg/dL from peak) Exclusion Criteria: * RASi allergy or contraindication (i.e., angioedema, bilateral renal artery stenosis) * Ongoing dialysis requirement * Pregnant or breastfeeding * Prisoner * Palliative or hospice care involvement * Unable to consent * No enteral route of medication administration * Clinician judgment
About the study
The goal of this pilot clinical trial is to learn if early restart of renin-angiotensin system inhibitor (RASi) medications is feasible and well-tolerated in hospitalized patients with acute kidney injury (AKI). Researchers will compare early RASi restart to usual care.
Study participants will restart RASi per study protocol, obtain a lab test in 1-2 weeks if RASi restarted in the hospital and not collected as part of routine care, and answer questions at the 90-day follow-up.
What is being tested
- Early RASi restart strategy (drug)
- Usual Care (drug)
Sponsor: University of California, San Francisco · Participants: 60 · Started: Sep 1, 2026
Contact the study team
- Yuenting D Kwong, MD MAS · Phone: 415-514-7371
Official record on ClinicalTrials.gov — NCT07734636
Locations in the U.S.
| California | University of California, San Francisco, San Francisco |
Conditions
From ClinicalTrials.gov, data retrieved Oct 2, 2026. Each study sets its own eligibility; the study team decides who can join.